Florian Schlotter1, Arda Halu1,2, Shinji Goto1, Mark C Blaser1, Simon C Body3, Lang H Lee1, Hideyuki Higashi1, Daniel M DeLaughter4, Joshua D Hutcheson1,5, Payal Vyas1, Tan Pham1, Maximillian A Rogers1, Amitabh Sharma2, Christine E Seidman4,6,7, Joseph Loscalzo6, Jonathan G Seidman4, Masanori Aikawa1,2,8, Sasha A Singh1, Elena Aikawa1,8. 1. Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (F.S., A.H., S.G., M.C.B., L.H.L., H.H., J.D.H., P.V., T.P., M.A.R., M.A., S.A.S., E.A.). 2. Channing Division of Network Medicine (A.H., A.S., M.A.). 3. Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Center for Perioperative Genomics and Department of Anesthesiology, Brigham and Women's Hospital, Boston, MA (S.C.B.). 4. Department of Genetics, Harvard Medical School, Boston, MA (D.M.D., C.E.S., J.G.S.). 5. Department of Biomedical Engineering, Florida International University, Miami (J.D.H.). 6. Department of Medicine, Brigham and Women's Hospital, Boston, MA (C.E.S., J.L.). 7. Howard Hughes Medical Institute, Chevy Chase, MD (C.E.S.). 8. Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.A., E.A.).
Abstract
BACKGROUND: No pharmacological therapy exists for calcific aortic valve disease (CAVD), which confers a dismal prognosis without invasive valve replacement. The search for therapeutics and early diagnostics is challenging because CAVD presents in multiple pathological stages. Moreover, it occurs in the context of a complex, multi-layered tissue architecture; a rich and abundant extracellular matrix phenotype; and a unique, highly plastic, and multipotent resident cell population. METHODS: A total of 25 human stenotic aortic valves obtained from valve replacement surgeries were analyzed by multiple modalities, including transcriptomics and global unlabeled and label-based tandem-mass-tagged proteomics. Segmentation of valves into disease stage-specific samples was guided by near-infrared molecular imaging, and anatomic layer-specificity was facilitated by laser capture microdissection. Side-specific cell cultures were subjected to multiple calcifying stimuli, and their calcification potential and basal/stimulated proteomes were evaluated. Molecular (protein-protein) interaction networks were built, and their central proteins and disease associations were identified. RESULTS: Global transcriptional and protein expression signatures differed between the nondiseased, fibrotic, and calcific stages of CAVD. Anatomic aortic valve microlayers exhibited unique proteome profiles that were maintained throughout disease progression and identified glial fibrillary acidic protein as a specific marker of valvular interstitial cells from the spongiosa layer. CAVD disease progression was marked by an emergence of smooth muscle cell activation, inflammation, and calcification-related pathways. Proteins overrepresented in the disease-prone fibrosa are functionally annotated to fibrosis and calcification pathways, and we found that in vitro, fibrosa-derived valvular interstitial cells demonstrated greater calcification potential than those from the ventricularis. These studies confirmed that the microlayer-specific proteome was preserved in cultured valvular interstitial cells, and that valvular interstitial cells exposed to alkaline phosphatase-dependent and alkaline phosphatase-independent calcifying stimuli had distinct proteome profiles, both of which overlapped with that of the whole tissue. Analysis of protein-protein interaction networks found a significant closeness to multiple inflammatory and fibrotic diseases. CONCLUSIONS: A spatially and temporally resolved multi-omics, and network and systems biology strategy identifies the first molecular regulatory networks in CAVD, a cardiac condition without a pharmacological cure, and describes a novel means of systematic disease ontology that is broadly applicable to comprehensive omics studies of cardiovascular diseases.
BACKGROUND: No pharmacological therapy exists for calcific aortic valve disease (CAVD), which confers a dismal prognosis without invasive valve replacement. The search for therapeutics and early diagnostics is challenging because CAVD presents in multiple pathological stages. Moreover, it occurs in the context of a complex, multi-layered tissue architecture; a rich and abundant extracellular matrix phenotype; and a unique, highly plastic, and multipotent resident cell population. METHODS: A total of 25 human stenotic aortic valves obtained from valve replacement surgeries were analyzed by multiple modalities, including transcriptomics and global unlabeled and label-based tandem-mass-tagged proteomics. Segmentation of valves into disease stage-specific samples was guided by near-infrared molecular imaging, and anatomic layer-specificity was facilitated by laser capture microdissection. Side-specific cell cultures were subjected to multiple calcifying stimuli, and their calcification potential and basal/stimulated proteomes were evaluated. Molecular (protein-protein) interaction networks were built, and their central proteins and disease associations were identified. RESULTS: Global transcriptional and protein expression signatures differed between the nondiseased, fibrotic, and calcific stages of CAVD. Anatomic aortic valve microlayers exhibited unique proteome profiles that were maintained throughout disease progression and identified glial fibrillary acidic protein as a specific marker of valvular interstitial cells from the spongiosa layer. CAVD disease progression was marked by an emergence of smooth muscle cell activation, inflammation, and calcification-related pathways. Proteins overrepresented in the disease-prone fibrosa are functionally annotated to fibrosis and calcification pathways, and we found that in vitro, fibrosa-derived valvular interstitial cells demonstrated greater calcification potential than those from the ventricularis. These studies confirmed that the microlayer-specific proteome was preserved in cultured valvular interstitial cells, and that valvular interstitial cells exposed to alkaline phosphatase-dependent and alkaline phosphatase-independent calcifying stimuli had distinct proteome profiles, both of which overlapped with that of the whole tissue. Analysis of protein-protein interaction networks found a significant closeness to multiple inflammatory and fibrotic diseases. CONCLUSIONS: A spatially and temporally resolved multi-omics, and network and systems biology strategy identifies the first molecular regulatory networks in CAVD, a cardiac condition without a pharmacological cure, and describes a novel means of systematic disease ontology that is broadly applicable to comprehensive omics studies of cardiovascular diseases.
Authors: Jörg Menche; Amitabh Sharma; Maksim Kitsak; Susan Dina Ghiassian; Marc Vidal; Joseph Loscalzo; Albert-László Barabási Journal: Science Date: 2015-02-20 Impact factor: 47.728
Authors: Jesper Hjortnaes; Jonathan Butcher; Jose-Luiz Figueiredo; Mark Riccio; Rainer H Kohler; Kenneth M Kozloff; Ralph Weissleder; Elena Aikawa Journal: Eur Heart J Date: 2010-07-02 Impact factor: 29.983
Authors: Ralf Koos; Vincent Brandenburg; Andreas Horst Mahnken; Georg Mühlenbruch; Sven Stanzel; Rolf W Günther; Jürgen Floege; Willy Jahnen-Dechent; Malte Kelm; Harald Peter Kühl Journal: Eur Heart J Date: 2009-05-08 Impact factor: 29.983
Authors: Jordan D Miller; Yi Chu; Robert M Brooks; Wayne E Richenbacher; Ricardo Peña-Silva; Donald D Heistad Journal: J Am Coll Cardiol Date: 2008-09-02 Impact factor: 24.094
Authors: Charu Munjal; Anil G Jegga; Amy M Opoka; Ivan Stoilov; Russell A Norris; Craig J Thomas; J Michael Smith; Robert P Mecham; Giorgio M Bressan; Robert B Hinton Journal: Physiol Rep Date: 2017-03
Authors: Anna E Bortnick; Shuo Xu; Ryung S Kim; Bryan Kestenbaum; Joachim H Ix; Nancy S Jenny; Ian H de Boer; Erin D Michos; George Thanassoulis; David S Siscovick; Matthew J Budoff; Jorge R Kizer Journal: Atherosclerosis Date: 2019-04-13 Impact factor: 5.162
Authors: Alexia Hulin; Luis Hortells; M Victoria Gomez-Stallons; Anna O'Donnell; Kashish Chetal; Mike Adam; Patrizio Lancellotti; Cecile Oury; S Steven Potter; Nathan Salomonis; Katherine E Yutzey Journal: Development Date: 2019-03-12 Impact factor: 6.868
Authors: Michael A Raddatz; Tessa Huffstater; Matthew R Bersi; Bradley I Reinfeld; Matthew Z Madden; Sabrina E Booton; W Kimryn Rathmell; Jeffrey C Rathmell; Brian R Lindman; Meena S Madhur; W David Merryman Journal: Arterioscler Thromb Vasc Biol Date: 2020-04-16 Impact factor: 8.311
Authors: Jihyeon Lim; Jennifer T Aguilan; Rani S Sellers; Fnu Nagajyothi; Louis M Weiss; Ruth Hogue Angeletti; Anna E Bortnick Journal: J Mol Histol Date: 2020-08-13 Impact factor: 2.611